BioCentury
ARTICLE | Clinical News

AEVI-001: Ph II/III SAGA data

March 23, 2017 8:51 PM UTC

Top-line data from the double-blind, U.S. Phase II/III SAGA trial in 96 evaluable ADHD patients ages 12-17 with genetic disorders impacting mGluRs showed that twice-daily oral AEVI-001 missed the prim...